Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
Experts claim it could be game-changing for people with obesity, although it is not licensed for non-diabetics
Our adorable capybara coach nudges you to hit daily protein, fiber, water, and exercise targets
Liraglutide in an adolescent population with obesity: a randomized, double-blind, placebo-controlled 5-week trial to assess safety, tolerability, and pharmacokinetics of liraglutide in adolescents aged 12-17 Years
Results were similar when stratified by cooccurring medical conditions, with a 38% lower rate of opioid poisoning in those with type 2 diabetes and a semaglutide/tirzepatide-type prescription, 33% lower among those with obesity, and 35% lower among those with both type 2 diabetes and obesity
